Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
AAA SMCs demonstrated twofold greater expression of MMP-2 messenger (m)RNA (P < .05) and 7.3-fold greater MMP-9 expression (P < .01) than NAA-SMCs.
|
24080131 |
2014 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
MMP-9 in AAA group at T14 (p<0.05 compared with T7 and p<0.005 compared with T0) and calprotectin in AAA group at T14 (p<0.001 compared with T7 and T0) continued to significantly increase at all times.
|
28155626 |
2018 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
MMP-9 deficiency augmented AngII-induced AAA.
|
28420827 |
2017 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MMP9 rs2234681 microsatellite was the only genetic determinant of TE/A in AAA patients (P = .003), followed by hypercholesterolemia and antiplatelet use.
|
29291905 |
2018 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLG4B, which encodes the 92-kDa form of type IV collagenase, is a candidate gene for AAA.
|
7762981 |
1995 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A recently published genome wide association study of abdominal aortic aneurysms (AAA), based on pooled case control data of European ancestry, identified four new loci for AAA: SMYD2 (top single nucleotide polymorphism [SNP] rs1795061), LINC00540 (rs9316871), PCIF1/MMP9/ZNF335 (rs3827066), and ERG (rs2836411).
|
31680049 |
2020 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Allografts in WT recipients developed intimal hyperplasia, whereas allografts in IFN-gamma receptor-deficient (GRKO) hosts developed severe AAA formation associated with markedly increased levels of MMP-9 and MMP-12.
|
15254597 |
2004 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Although recruitment closed early because of increasing statin use among eligible patients, with only 21 patients we demonstrated a 40% reduction in MMP-9 levels in the AAA wall in patients randomised to simvastatin.
|
17574455 |
2007 |
Aortic Aneurysm, Abdominal
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analyses identified MMP-9 p-2502 single nucleotide polymorphism (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.31-0.94; P = .029) as a significant confound discriminating between control vs slow-growth AAA, MMP-9 D165N (OR, 0.49; 95% CI, 0.26-0.95; P = .035) and LRP1 (OR, 4.99; 95% CI, 1.13-22.1; P = .034) between control vs aggressive-growth AAAs, and methyltetrahydrofolate reductase (OR, 2.99; 95% CI, 1.01-8.86; P = .048), MMP-9 p-2502 (OR, 2.19; 95% CI, 1.05-4.58; P = .037), and LRP1 (OR, 4.96; 95% CI, 1.03-23.9; P = .046) as the statistically significant confounds distinguishing slow-growth AAAs vs aggressive-growth AAAs.
|
24801553 |
2014 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
As to mechanism, we found that RAGE was coexpressed in AAA macrophages with MMP-9, a promoter of matrix degradation, which is known to induce AAA.
|
19652591 |
2009 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
B-cell-deficient muMT mice showed suppression of AAA development that was associated with reduced activation of Syk and less expression of matrix metalloproteinase-9.
|
29545260 |
2018 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
LHGDN |
Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm.
|
17964292 |
2008 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Densitometric analysis confirmed differences in expression for 20 of these gene products between AAAs and normal aorta, with the greatest increases seen for myeloid cell nuclear differentiation antigen (31-fold), cathepsin H (30-fold), platelet-derived growth factor-A (23-fold), apolipoprotein E (13-fold), gelatinase B/matrix metalloproteinase-9 (12-fold), and interleukin-8 (11-fold).
|
11436088 |
2001 |
Aortic Aneurysm, Abdominal
|
0.600 |
Therapeutic
|
disease |
RGD |
Downregulation of remodelling enzymatic activity induced by an angiotensin-converting enzyme inhibitor (perindopril) reduces the degeneration of experimental abdominal aortic aneurysms in a rat model.
|
21256058 |
2011 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Embelin inhibited tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6, IL‑18 and malondialdehyde (MDA) level activities, increased superoxide dismutase, glutathione (GSH) and GSH peroxidase level activities and inhibited MDA level activities in AAA mice Embelin suppressed the secretion of matrix metalloproteinase‑9 protein expression, monocyte chemoattractant protein‑2 activity and epithelial neutrophil‑activating peptide expression levels in AAA mice.
|
29956759 |
2018 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelial MMP-9 drives the inflammatory response in abdominal aortic aneurysm (AAA).
|
29312500 |
2017 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ex vivo experiments showed that mRNA expressions of TNF-α, MMP-2, and MMP-9 in the cultured AAA tissue were decreased by exogenous TG2, whereas were increased by cystamine.
|
20615646 |
2010 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
CTD_human |
Experimental abdominal aortic aneurysm formation is associated with early increases in MnSOD expression and an increase in MMP-9 activity.
|
17196988 |
2007 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Gambogic acid treatment markedly decreased the levels of proinflammatory cytokines and oxidative stress factors, and transforming growth factor‑β (TGF‑β) and matrix metalloproteinase (MMP)‑2 and MMP‑9 protein expression in AAA mice.
|
30535428 |
2019 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gelatin zymography showed that quercetin eliminated matrix metalloproteinase (MMP)‑2 and MMP‑9 activation during AAA formation.
|
24337353 |
2014 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we show that blockade of IL-12p40 in the early phase of aneurysm development suppresses macrophage expansion, inflammatory cytokine and MMP-9 production and mitigates AAA development.
|
31320700 |
2019 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Higher MMP-9 expression was also found in SMCs and macrophages of both AAA and AOD specimens, while higher TIMP-1/TIMP-2 were predominantly observed in the lymphocytes and macrophages of the aneurysm.
|
29687775 |
2017 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
In a comparison of ruptured AAA biopsies, MMP-8 and -9 levels were significantly elevated in the 12 rupture site biopsies compared with their 12 paired anterior wall biopsies, whereas other MMPs and TIMPs showed no difference (MMP-8, P<0.001; MMP-9, P=0.01).
|
16432074 |
2006 |
Aortic Aneurysm, Abdominal
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In a mouse CaCl(2)-induced AAA model, the expression of HMGB1 was increased compared with that in sham, and was positively correlated with matrix metalloproteinase (MMP)-2 and MMP-9 activity.
|
22365948 |
2012 |
Aortic Aneurysm, Abdominal
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, the protein expressions of several key components involved in AAA pathogenic features are as follows: matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2 for elastin degradation; collagen type 1 alpha 1 for compensatory collagen synthesis; monocyte chemoattractant protein-1 for inflammation, were also evaluated.
|
28288890 |
2017 |